The sustained functional improvement across multiple endpoints strengthens the case for Accelerated Approval. Watch for the ACHIEVE REC topline data in Q1 2027 and the Phase 3 HARMONIA confirmatory trial enrollment progress. The pooled dose group heterogeneity means the registrational dose cohort (6.8 mg/kg Q8W, N=6) remains the cleanest efficacy signal.
Price Chart
Executive Summary
Dyne Therapeutics presented additional one-year efficacy data from the Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 at WMS/AANEM, showing functional improvement across multiple measures versus baseline, placebo, and a matched natural history cohort. The company reiterated expectations for topline data from the registrational expansion cohort in Q1 2027 and a potential U.S. Accelerated Approval submission in Q3 2027. The data support the drug's mechanism but come from a pooled dose group with heterogeneous exposures, not the registrational dose alone.
Key Facts
- Pooled dose group (N=25-26) showed vHOT improvement of 3.2 seconds at 6 months vs. 0.4 second increase in placebo (3.6 sec relative improvement).
- At 12 months, pooled dose group improved on 5xSTS by 1.2 seconds and 10MWR by 0.3 seconds vs. baseline, diverging from matched natural history cohort on 10MWR.
- QMT total and hand grip strength improved by 4.8% predicted vs. baseline at 12 months, diverging from natural history.
- MDHI total score improved by 25.2% vs. baseline at 12 months, diverging from unmatched natural history cohort (N=410).
- Mean baseline vHOT of ACHIEVE REC (N=71) is 8.3 seconds; topline data expected Q1 2027, with potential BLA submission for Accelerated Approval in Q3 2027.
- Z-basivarsen has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA, plus Orphan Drug designations from EMA and MHLW Japan.
- No related serious treatment emergent adverse events identified; favorable safety profile.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue. Positive efficacy data supports potential regulatory filing and future commercial opportunity in ~40,000 U.S. DM1 patients.
Risk Factors
- Pooled dose group includes heterogeneous dose exposures; only 8 of 26 participants received the registrational dose for the full 12 months.
- Topline data from the REC in Q1 2027 is the next binary catalyst; failure to meet the vHOT primary endpoint would derail Accelerated Approval.
- No approved disease-modifying treatments for DM1 exist, so regulatory path is novel and uncertain.
- Competing DM1 programs from other companies could emerge before Dyne's potential approval.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371326 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $15.62 | awaiting T+20 | — | $16.94 (+8.45%) |
Oct 12, 2026 15d ago | Institutional Cluster | $15.96 | awaiting T+20 | — | $16.94 (+6.14%) |
Sep 29, 2026 28d ago | Press Release | $16.11 | awaiting T+20 | — | $16.94 (+5.15%) |
Sep 8, 2026 7w ago | Insider Cluster | $19.19 $15.97 | ▼ −16.78% | ▼ −18.72% | $16.94 (−11.72%) |
Aug 17, 2026 10w ago | Insider Cluster | $26.00 $17.31 | ▲ +33.44% | ▲ +31.70% | $16.94 (+34.85%) |
Aug 14, 2026 10w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $16.94 (−35.22%) |
Aug 13, 2026 10w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $16.94 (+34.09%) |
Aug 13, 2026 10w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $16.94 (−34.09%) |
Aug 13, 2026 10w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $16.94 (−34.09%) |
Jul 29, 2026 12w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $16.94 (−34.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers